Dren Bio
Foster City, US · Founded 2019 · Delaware corporation · 8 known investors
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical Devices
Founders & leadership
NT
Nenad TomasevicExecutive Officer, Director
IT
Ivan TrifunovichDirector
JW
John WesleyDirector
Investors · 8
8VCAustin · $100K – $50Mvia Alex Kolicich · board
Aisling CapitalNew York
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K
Taiho Ventures, LLCMenlo Parkvia Sakae Asanuma · board
HBM Healthcare InvestmentsreportedZug
Olive Tree CapitalreportedBoston
SR One Capital ManagementreportedRedwood Cityvia Rajeev Dadoo · board
Reported raises · per SEC filings
Form D private placements▶$62.5MraisedMar 2022 · 27 investors · BiotechnologyRule 506(b)
▶$62.5MraisedMar 2022 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rajeev DadooDirector
- Nenad TomasevicExecutive Officer, Director
- Andrew N. SchiffDirector
- Alex KolicichDirector
- Chandra LeoDirector
- Kenneth R LuehrsenDirector
- Sakae AsanumaDirector
- Offering amount
- $80M
- Amount sold
- $62.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$25.5MraisedNov 2020 · 11 investors · BiotechnologyRule 506(b)
▶$25.5MraisedNov 2020 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alex KolicichDirector
- Rajeev DadooDirector
- Sakae AsanumaDirector
- John WesleyDirector
- Nenad TomasevicExecutive Officer, Director
- Offering amount
- $60M
- Amount sold
- $25.5M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5.1MraisedJul 2019 · 19 investors · OtherRule 506(b)
▶$5.1MraisedJul 2019 · 19 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Nenad TomasevicExecutive Officer, Director
- Ivan TrifunovichDirector
- John WesleyDirector
- Offering amount
- $6M
- Amount sold
- $5.1M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platformbusinesswire.com · 2022
- Dren Bio, Inc. Licenses ATX-Gx™ Transgenic Mice Platformalloytx.com · 2022
- Dren Bio Raises $60 Million to Develop Therapies for Rare Cancers - Global Genesglobalgenes.org · 2020
- Dren Bio Raises $60M in Series A Financing - FinSMEsfinsmes.com · 2020